Abstract:Osteoarthritis (OA) is the most common degenerative joint disorder and genetic factors have been shown to have a significant role in its etiology. The first metatarsophalangeal joint (MTP I) is highly susceptible to development of OA due to repetitive mechanical stress during walking. We used whole exome sequencing to study genetic defect(s) predisposing to familial early-onset bilateral MTP I OA inherited in an autosomal dominant manner. A nonsynonymous single nucleotide variant rs41310883 (c.524C>T, p.Thr175… Show more
“…According to these results, in the presence of PEI-EVs, qRT-PCR showed upregulation of key genes involved in the bone-differentiation pathway, such as TUFT1, TFIP11, BMP2-BMP4, and TGFB. TUFT1 expression in cartilage has demonstrated to be strongest in the deep, mineralizing zones, 51 and its expression has been shown to be regulated in vitro by HIF1α and Hedgehog pathways, both essential elements involved in cartilage and bone formation. 52 TFIP11 is a gene involved in pre-mRNA splicing, specifically in spliceosome disassembly during late-stage splicing events that may play a role in the differentiation of ameloblasts and odontoblasts or in the formation of the extracellular mineralized matrix.…”
PurposeThe combination of oral derived stem cells and 3-D scaffolds is considered advantageous in bone repair. In particular, collagen membranes possess ideal biological properties and can support infiltration and proliferation of osteoblasts, promoting bone regeneration. Our study aimed to develop a new biocompatible osteogenic construct composed of a commercially available collagen membrane (Evolution [Evo]), human periodontal-ligament stem cells (hPDLSCs) enriched with extracellular vesicles (EVs), or polyethylenimine (PEI)-engineered EVs (PEI-EVs).MethodsOsteogenic ability and expression of osteogenic genes were evaluated in vitro in hPDLSCs cultured with or without Evo, with Evo and EVs, or PEI-EVs. In addition, the bone-regeneration capacity of Evo, Evo enriched with hPDLSCs, Evo enriched with hPDLSCs and EVs/PEI-EVs was investigated in rats subjected to calvarial defects.ResultsOur results showed that Evo enriched with EVs and PEI-EVs showed high biocompatibility and osteogenic properties in vitro and in vivo. In addition, quantitative reverse-transcription polymerase chain reaction demonstrated the upregulation of osteogenic genes, such as TGFB1, MMP8, TUFT1, TFIP11, BMP2, and BMP4, in the presence of PEI-EVs. Upregulation of BMP2/4 was confirmed for Evo enriched with PEI-EVs and hPDLSCs both in vitro by Western blot and in vivo by immunofluorescence.ConclusionOur results indicated that Evo enriched with hPDLSCs and PEI-EVs is able to promote a bone-regeneration process for the treatment of calvarium and ossification defects caused by accidental or surgery trauma. In particular, PEI-EVs had a significant role in activation of the osteogenic process.
“…According to these results, in the presence of PEI-EVs, qRT-PCR showed upregulation of key genes involved in the bone-differentiation pathway, such as TUFT1, TFIP11, BMP2-BMP4, and TGFB. TUFT1 expression in cartilage has demonstrated to be strongest in the deep, mineralizing zones, 51 and its expression has been shown to be regulated in vitro by HIF1α and Hedgehog pathways, both essential elements involved in cartilage and bone formation. 52 TFIP11 is a gene involved in pre-mRNA splicing, specifically in spliceosome disassembly during late-stage splicing events that may play a role in the differentiation of ameloblasts and odontoblasts or in the formation of the extracellular mineralized matrix.…”
PurposeThe combination of oral derived stem cells and 3-D scaffolds is considered advantageous in bone repair. In particular, collagen membranes possess ideal biological properties and can support infiltration and proliferation of osteoblasts, promoting bone regeneration. Our study aimed to develop a new biocompatible osteogenic construct composed of a commercially available collagen membrane (Evolution [Evo]), human periodontal-ligament stem cells (hPDLSCs) enriched with extracellular vesicles (EVs), or polyethylenimine (PEI)-engineered EVs (PEI-EVs).MethodsOsteogenic ability and expression of osteogenic genes were evaluated in vitro in hPDLSCs cultured with or without Evo, with Evo and EVs, or PEI-EVs. In addition, the bone-regeneration capacity of Evo, Evo enriched with hPDLSCs, Evo enriched with hPDLSCs and EVs/PEI-EVs was investigated in rats subjected to calvarial defects.ResultsOur results showed that Evo enriched with EVs and PEI-EVs showed high biocompatibility and osteogenic properties in vitro and in vivo. In addition, quantitative reverse-transcription polymerase chain reaction demonstrated the upregulation of osteogenic genes, such as TGFB1, MMP8, TUFT1, TFIP11, BMP2, and BMP4, in the presence of PEI-EVs. Upregulation of BMP2/4 was confirmed for Evo enriched with PEI-EVs and hPDLSCs both in vitro by Western blot and in vivo by immunofluorescence.ConclusionOur results indicated that Evo enriched with hPDLSCs and PEI-EVs is able to promote a bone-regeneration process for the treatment of calvarium and ossification defects caused by accidental or surgery trauma. In particular, PEI-EVs had a significant role in activation of the osteogenic process.
“…Osteoarthritis (OA), the most common degenerative joint disease, is characterized by progressive loss of cartilage, periarticular bone changes and chronic synovitis that lead to joint swelling and pain . OA most often affects the knees, hips, neck, finger joints and lower back .…”
“…The study of rare variants in affected families is a powerful way to identify gene variants with a determinate effect on disease development. [47][48][49][50] Using the UPDB, we have identified 240 large multigenerational, high-risk pedigrees segregating EOA as an apparent dominate trait. Although a previous study described association of EOA in sibling pairs 24 , our study is the first to identify a large number of multigenerational EOA pedigrees and determine relative risk among family members.…”
Objectives: Erosive hand osteoarthritis (EOA) is a severe and rapidly progressing form of osteoarthritis. Its etiology remains largely unknown, which has hindered development of successful treatments. Our primary goal was to test the hypothesis that EOA would demonstrate familial clustering in a large statewide population linked to genealogical records, which would suggest a genetic contribution to the pathogenesis of this condition. Our secondary purpose was to determine the association of potential risk factors with EOA.
Methods: Patients diagnosed with EOA were identified by searching medical records from a comprehensive statewide database, the Utah Population Database (UPDB). Affected individuals were then mapped to pedigrees to identify high-risk families with excess clustering of EOA as defined by a Familial Standardized Incidence Ratio (FSIR) of ≥ 2.0. The magnitude of familial risk of EOA in related individuals was calculated using Cox regression models. Association of potential EOA risk factors was analyzed using conditional logistic regression and logistic regression models.
Results: We identified 703 affected individuals linked to 240 unrelated high-risk pedigrees with excess clustering of EOA (FSIR ≥ 2.0). The relative risk of developing EOA was significantly elevated in first-degree relatives. There was a significant association with the diagnosis of EOA and age, sex, diabetes, and obesity.
Conclusions: Familial clustering of EOA observed in a statewide database indicates a potential genetic contribution to the etiology of the disease. Identification of causal gene variants in these high-risk families may provide insight into the genes and pathways that contribute to EOA onset and progression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.